Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 11, 2023
Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) announced today that it has signed a Renewable-Linked Power Purchase Agreement (PPA) with Australian energy provider, AGL. AGL was awarded...
-
Oct 11, 2023Boosting exhausted T cells: Dr Daniel Utzschneider, Melbourne and On the path to a liver cancer vaccine: Dr Ankur Sharma, Perth are the two research programs selected as a part of the global biotechnology company’s long-standing promise to support scientists in Australia
MELBOURNE – 12 October 2023 – Two Australian scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. They are each developing new kinds of...
-
Oct 3, 2023CSL’s Global Research Acceleration Initiative Freshly Inks Promising Research Partnerships in Europe and, for the first time, Asia and the UK
MELBOURNE, AUSTRALIA – 04 October 2023 – CSL’s Research Acceleration Initiative (RAI) continues to expand its reach with seven medical researchers awarded new RAI partnerships, including up...
-
Sep 5, 2023
EMA application supported by Phase 3 primary vaccination study demonstrating primary efficacy endpoint was met An additional Phase 3 booster study demonstrating non-inferiority of immune response...
-
Aug 27, 2023State-of-the-art facility strengthens Melbourne’s world-class biomedical precinct.
Melbourne, Australia – 21 August 2023 – Australia today ushered in a new era in scientific and medical innovation, with Prime Minister of Australia, Anthony Albanese officially opening CSL’s...
-
Aug 17, 2023
Global biotechnology leader CSL (ASX: CSL) (USOTC: CSLLY) announced today that Jeffrey Ball, an established global leader across multiple disciplines and functions, has been appointed Chief...
-
Mar 27, 2023
The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines WALTHAM, Mass., March 27, 2023 /PRNewswire/ -- Global biotechnology...
-
Mar 1, 2023
Significant reduction in number of attacks support the potential of once-monthly garadacimab as a prophylactic therapy for patients with hereditary angioedema KING OF PRUSSIA, Pa., March 1, 2023...
-
Feb 26, 2023
Majority of patients were attack free during the entire six-month treatment period (61.5%) Study results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions...
-
Feb 23, 2023
Data follow the historic approval of the first gene therapy for hemophilia B, which reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates...